Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using
raloxifene and tamoxifen may fight breast cancer by blocking the uptake of estrogen by the
tumor cells.
PURPOSE: Randomized double-blinded clinical trial to compare the effectiveness of raloxifene
with that of tamoxifen in preventing breast cancer in postmenopausal women.
Phase:
Phase 3
Details
Lead Sponsor:
NSABP Foundation Inc
Collaborators:
AstraZeneca Eli Lilly and Company National Cancer Institute (NCI)